Free Republic

Yesterday the Expose published an article which highlighted just a few of the various diseases that were found to be potentially caused by parasites, including cancers. A recent review of nine published research papers by Doctor William Makis further supports the views in the article, but Dr Makis is more qualified to say “it is a reasonable hypothesis that COVID-19 mRNA Vaccine Turbo Cancer patients could benefit significantly from anti-parasitic drugs.” One anti parasitic drug in particular, Fenbendazole, however, has not been sanctioned for human use by the FDA, but despite lacking “official” approval, it is cheap, safe and more...

Adjuvant therapy with atezolizumab (Tecentriq) and bevacizumab (Avastin) increased recurrence-free survival of patients with hepatocellular carcinoma (HCC) following surgical resection or ablation, according to the results from the phase III IMbrave050 clinical trial. The mainstays of curative therapies for early-stage HCC include surgical resection and thermal ablation, a treatment that destroys the cancer cells with heat or cold. However, the risk of recurrence reaches 70%–80% five years after resection or ablation with curative intent, said Pierce Chow, FRCS(E), Ph.D. According to the results of an interim analysis conducted after a median follow-up of 17.4 months, the trial met its primary...

For patients with advanced renal cell carcinoma, progression-free survival and overall survival are improved with lenvatinib plus pembrolizumab versus sunitinib, according to a study. Toni K. Choueiri, M.D. and colleagues conducted a protocol-prespecified updated overall survival analysis of the phase 3 CLEAR trial. Patients with clear-cell advanced renal cell carcinoma who had not received any systemic anticancer therapy were eligible and randomly assigned to receive lenvatinib plus pembrolizumab, lenvatinib plus everolimus, or sunitinib (355, 357, and 357, respectively). This updated analysis did not report on patients in the lenvatinib plus everolimus group. The median follow-up for progression-free survival was 27.8...

Washington -- Nine military officers who had worked decades ago at a nuclear missile base in Montana have been diagnosed with blood cancer and there are “indications” the disease may be linked to their service, according to military briefing slides obtained by The Associated Press. One of the officers has died. All of the officers, known as missileers, were assigned as many as 25 years ago to Malmstrom Air Force Base, home to a vast field of 150 Minuteman III intercontinental ballistic missile silos. The nine officers were diagnosed with non-Hodgkin lymphoma, according to a January briefing by U.S. Space...

In an international, multicenter Phase II clinical trial led by The University of Texas MD Anderson Cancer Center, 63.3% of patients with stage II–IV cutaneous squamous cell carcinoma (CSCC) saw their tumors nearly or completely disappear when treated with immunotherapy before surgery. The anti-PD1 therapy cemiplimab was well-tolerated, and the study met its primary endpoint with a pathologic complete response (pCR) rate of 50.6%, meaning no tumor cells were found at surgery. Another 12.7% of patients had a major pathological response (MPR), with less than 10% viable tumor found at surgery. The responses were confirmed by independent central pathologic review....

A small team of Israeli scientists think they might have found the first complete cure for cancer. “We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, of a new treatment being developed by his company, Accelerated Evolution Biotechnologies Ltd. (AEBi), which was founded in 2000 in the ITEK incubator in the Weizmann Science Park. AEBi developed the SoAP platform, which provides functional leads to very difficult targets. “Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at...

Imagine if you could turn aggressive cancer cells into harmless fat. Scientists in Switzerland say they've done just that, in a new study in mice. By taking advantage of the "plasticity," or adaptability, of certain cancer cells during metastasis, the researchers were able to coax breast cancer cells in mice into becoming fat cells. The scientists accomplished this using a combination of two drugs, both of which are already approved for use in humans by the U.S. Food and Drug Administration (FDA). The treatment didn't convert all of the cancer cells into fat cells, but it did stop the cancer's...

A GENETICALLY modified virus that kills cancer cells and destroys their hiding places has been developed by British scientists. It targets both cancer cells and healthy cells that are tricked into protecting the cancer from the immune system. Fibroblasts, the most common type of cell in connective tissues, are vital in the body's healing process, but they can get hijacked by cancer-associated fibroblasts or CAFs. These then help tumours grow, spread and evade therapy. The new treatment, a form of immunotherapy developed by Oxford University scientists, attacks carcinomas - the most ­common type of cancer. Currently, any therapy that kills...

People who develop a common benign skin carcinoma multiple times may be at increased risk for other more serious cancers, including blood, breast, colon and prostate cancers, a new study finds. Stanford University researchers suspect the increased cancer susceptibility is caused by mutations in certain genes responsible for making proteins that repair DNA damage, according to the study published in JCI Insight. Multiple episodes of basal cell carcinoma are simply a sign of this susceptibility. The new findings don’t mean anyone who develops a basal cell carcinoma once or twice has a higher risk of developing other cancers, said study...

PITTSBURGH (KDKA) – Can cellphones really cause cancer? It’s been a question that’s dogged researchers for years. However, a group of experts say the results of some tests are pretty surprising. Millions of people constantly call, text, click, take pictures and play on cellphones. Even the top cellular radiation researchers from around the world have a hard time untethering. But, they gathered recently in North Carolina to talk about cellphone concerns and whether they really do increase the chances of developing cancer. The panel voted that the results from years of testing on mice and rats were more significant than...

In the rich world, cancer therapy is expensive. In the developing world, it may not be available at all. Not only is cutting-edge technology in short supply, but so are things like electricity and medical personnel. The lack of necessary resources for basic healthcare is made obvious by the fact that, if diagnosed with cancer, a person in the developing world is more likely to die from it than a person in the developed world. To help alleviate this problem, cheap, uncomplicated, portable, and preferably non-surgical treatments that do not require electricity are needed. Now, a team of researchers from...

Scientists have discovered a chemical extract in green tea that can treat two types of skin cancer, without producing the harmful side effects associated with chemotherapy.While the epigallocatechin gallate (EGCg) compound is too weak to make an impact when consumed in tea, scientists were able to kill or shrink two-thirds of cancer cells within a month when they applied the extract to tumor cells in the lab. What's more, the chemical compound did not appear to affect any other healthy cells or tissues in the body.Researchers from the universities of Strathclyde and Glasgow believe that their study is the first...

Scientists have identified a new compound that rapidly kills hepatocellular carcinoma (HCC) cells, the most common form of liver cancer and fifth most common cancer worldwide, while sparing healthy tissue. The compound, Factor Qunolinone Inhibitor 1 (FQI1), works by inhibiting an oncogene originally discovered by a team of researchers led by Devanand Sarkar, M.B.B.S., Ph.D., Harrison Scholar at Virginia Commonwealth University (VCU) Massey Cancer Center, Blick Scholar and assistant professor in the Department of Human and Molecular Genetics and member of the VCU Institute of Molecular Medicine at the VCU School of Medicine. Recently published in the journal Proceedings of...